The Latest Cardiac and Vascular News
Data presentations at AHA 2023 Meeting reinforce treatment with XARELTO® plus aspirin consistently reduces major cardiovascular events (MACE) as well as major adverse limb events (MALE) in complex patients with PAD Janssen continues commitment to supporting PAD patients with ongoing…
This is the first and only single tablet combination therapy to be submitted for review in Europe for this rare, progressive disease If approved, Janssen’s comprehensive PAH portfolio has the potential to cover all guideline-recommended treatment pathways BEERSE, Belgium, June […]
This is the first and only single tablet combination therapy application to be submitted for review in the U.S. for this rare, progressive disease If approved, Janssen’s comprehensive PAH portfolio has the potential to cover all guidelines-recommended treatment pathways […]
The Librexia program evaluating milvexian is unrivaled as the most comprehensive factor XIa inhibitor clinical development program to date and will provide extensive data from nearly 50,000 patients, with all three studies underway RARITAN, N.J., May 25, 2023 /PRNewswire/ — The Janssen Pharmaceutical […]
Findings presented at ACC.23 show XARELTO® plus aspirin provides a 33 percent reduction in acute limb ischemia following LER, with consistent benefit demonstrated at 30 days, 90 days and up to three years Patients who undergo LER are four times more […]
Head-to-head observational analysis showed XARELTO® as effective in treating cancer-associated thromboembolism (CAT) as apixaban Venous thromboembolism (VTE) is the second-leading cause of death in patients with cancer1 TITUSVILLE, N.J., Dec. 9, 2022 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today […]
Aprocitentan is an investigational antihypertensive drug with a novel mechanism of action RARITAN, N.J., Nov. 7, 2022 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with Idorsia Ltd, today announced results from the Phase 3 PRECISION study, which […]
Black Americans are up to four times more likely to have a PAD-related amputation,1 largely due to greater delays in care2 and less access to quality vascular care1 Save Legs. Change Lives.™ aims to reach more than 10 million Black Americans over […]
COMPASS open label extension study results support the long-term use of XARELTO® plus aspirin for vascular protection in patients with chronic CAD and/or PAD XATOA registry provides further evidence of the benefit of DPI for CAD and/or PAD patients at high risk of […]
Through Save Legs. Change Lives.™, Janssen seeks to elevate PAD research, collaboration, education and screening for communities placed at increased risk of cardiovascular disease TITUSVILLE, N.J., March 31, 2022 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the launch […]
